Literature DB >> 30208281

Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

Miguel Moutinho1, Juan F Codocedo1, Shweta S Puntambekar1, Gary E Landreth1.   

Abstract

Neurodegenerative diseases are characterized by a progressive loss of neurons that leads to a broad range of disabilities, including severe cognitive decline and motor impairment, for which there are no effective therapies. Several lines of evidence support a putative therapeutic role of nuclear receptors (NRs) in these types of disorders. NRs are ligand-activated transcription factors that regulate the expression of a wide range of genes linked to metabolism and inflammation. Although the activation of NRs in animal models of neurodegenerative disease exhibits promising results, the translation of this strategy to clinical practice has been unsuccessful. In this review we discuss the role of NRs in neurodegenerative diseases in light of preclinical and clinical studies, as well as new findings derived from the analysis of transcriptomic databases from humans and animal models. We discuss the failure in the translation of NR-based therapeutic approaches and consider alternative and novel research avenues in the development of effective therapies for neurodegenerative diseases.

Entities:  

Keywords:  Alzheimer's disease; Huntington's disease; Parkinson's disease; amyotrophic lateral sclerosis; neurodegenerative diseases; nuclear receptors

Year:  2018        PMID: 30208281      PMCID: PMC6636329          DOI: 10.1146/annurev-pharmtox-010818-021807

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  157 in total

1.  Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin.

Authors:  Kristina Endres; Falk Fahrenholz; Johannes Lotz; Christoph Hiemke; Stefan Teipel; Klaus Lieb; Oliver Tüscher; Andreas Fellgiebel
Journal:  Neurology       Date:  2014-10-24       Impact factor: 9.910

2.  Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes.

Authors:  Marta Valenza; Valerio Leoni; Joanna M Karasinska; Lara Petricca; Jianjia Fan; Jeffrey Carroll; Mahmoud A Pouladi; Elisa Fossale; Huu Phuc Nguyen; Olaf Riess; Marcy MacDonald; Cheryl Wellington; Stefano DiDonato; Michael Hayden; Elena Cattaneo
Journal:  J Neurosci       Date:  2010-08-11       Impact factor: 6.167

3.  Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson's disease.

Authors:  Sarah K Abbott; Andrew M Jenner; Adena S Spiro; Marijka Batterham; Glenda M Halliday; Brett Garner
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 4.  PPAR: a therapeutic target in Parkinson's disease.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  J Neurochem       Date:  2008-04-01       Impact factor: 5.372

5.  Rescue of Hypovitaminosis A Induces Non-Amyloidogenic Amyloid Precursor Protein (APP) Processing.

Authors:  Sven Reinhardt; Marcus O W Grimm; Christoph Stahlmann; Tobias Hartmann; Koichi Shudo; Taisuke Tomita; Kristina Endres
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 6.  RXR: from partnership to leadership in metabolic regulations.

Authors:  Béatrice Desvergne
Journal:  Vitam Horm       Date:  2007       Impact factor: 3.421

Review 7.  Tamibarotene: a candidate retinoid drug for Alzheimer's disease.

Authors:  Hiroshi Fukasawa; Madoka Nakagomi; Naoko Yamagata; Hiroshi Katsuki; Kohichi Kawahara; Kazuyoshi Kitaoka; Takami Miki; Koichi Shudo
Journal:  Biol Pharm Bull       Date:  2012       Impact factor: 2.233

8.  Identification of a new brain-specific transcription factor, NURR1.

Authors:  S W Law; O M Conneely; F J DeMayo; B W O'Malley
Journal:  Mol Endocrinol       Date:  1992-12

9.  Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease.

Authors:  Ingemar Björkhem; Anita Lövgren-Sandblom; Valerio Leoni; Steve Meaney; Lovisa Brodin; Lisette Salveson; Kristian Winge; Sven Pålhagen; Per Svenningsson
Journal:  Neurosci Lett       Date:  2013-09-10       Impact factor: 3.046

Review 10.  PPAR-γ: therapeutic prospects in Parkinson's disease.

Authors:  Anna R Carta
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

View more
  10 in total

Review 1.  Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing.

Authors:  José J M Vitória; Diogo Trigo; Odete A B da Cruz E Silva
Journal:  Cell Mol Life Sci       Date:  2022-01-28       Impact factor: 9.261

Review 2.  TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.

Authors:  Adam T Nelson; Yu Wang; Erik R Nelson
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

Review 3.  Retinoid X Receptor: Cellular and Biochemical Roles of Nuclear Receptor with a Focus on Neuropathological Involvement.

Authors:  Samridhi Sharma; Ting Shen; Nitin Chitranshi; Veer Gupta; Devaraj Basavarajappa; Soumalya Sarkar; Mehdi Mirzaei; Yuyi You; Wojciech Krezel; Stuart L Graham; Vivek Gupta
Journal:  Mol Neurobiol       Date:  2022-01-11       Impact factor: 5.682

4.  Importance of γ-secretase in the regulation of liver X receptor and cellular lipid metabolism.

Authors:  Esteban Gutierrez; Dieter Lütjohann; Anja Kerksiek; Marietta Fabiano; Naoto Oikawa; Lars Kuerschner; Christoph Thiele; Jochen Walter
Journal:  Life Sci Alliance       Date:  2020-04-30

5.  Systemic Candesartan Treatment Modulates Behavior, Synaptic Protein Levels, and Neuroinflammation in Female Mice That Express Human APOE4.

Authors:  Sarah B Scheinman; Steve Zaldua; Adedoyin Dada; Kateryna Krochmaliuk; Katherine Dye; Felecia M Marottoli; Gregory R J Thatcher; Leon M Tai
Journal:  Front Neurosci       Date:  2021-02-10       Impact factor: 4.677

Review 6.  Nuclear receptors of NR1 and NR4 subfamilies in the regulation of microglial functions and pathology.

Authors:  Hiroshi Katsuki
Journal:  Pharmacol Res Perspect       Date:  2021-12

Review 7.  From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.

Authors:  Yumeng Zhu; Ping Xu; Xuan Huang; Wen Shuai; Li Liu; Shuai Zhang; Rui Zhao; Xiuying Hu; Guan Wang
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

8.  Nuclear receptors NHR-49 and NHR-79 promote peroxisome proliferation to compensate for aldehyde dehydrogenase deficiency in C. elegans.

Authors:  Lidan Zeng; Xuesong Li; Christopher B Preusch; Gary J He; Ningyi Xu; Tom H Cheung; Jianan Qu; Ho Yi Mak
Journal:  PLoS Genet       Date:  2021-07-08       Impact factor: 5.917

9.  KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma.

Authors:  Xiuzhi Zhang; Jialing Zhang; Fenglan Gao; Shasha Fan; Liping Dai; Jinzhong Zhang
Journal:  Front Genet       Date:  2020-10-26       Impact factor: 4.599

10.  Autocrine Effects of Brain Endothelial Cell-Produced Human Apolipoprotein E on Metabolism and Inflammation in vitro.

Authors:  Felecia M Marottoli; Troy N Trevino; Xue Geng; Zarema Arbieva; Pinal Kanabar; Mark Maienschein-Cline; James C Lee; Sarah E Lutz; Leon M Tai
Journal:  Front Cell Dev Biol       Date:  2021-06-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.